Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Role of the FDA Thomas Abrams, R.Ph., M.B.A. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration October 26, 2004.

Published byHolly Hicks Modified over 8 years ago

Similar presentations

Presentation on theme: "The Role of the FDA Thomas Abrams, R.Ph., M.B.A. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration October 26, 2004."— Presentation transcript:

1 The Role of the FDA Thomas Abrams, R.Ph., M.B.A. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration October 26, 2004

2 Examples of Violations Minimization of risk information Unsubstantiated claims of efficacy or safety Unsubstantiated comparative claims Promotion of unapproved uses of drugs

3 Diovan Warning Letter Sales aid Unsubstantiated effectiveness claim Diovan delays progression to end stage renal disease (ESRD) in type 2 diabetic patients with hypertension No substantial evidence; other drugs have substantial evidence for this claim

4 Diovan WL (cont.) Data on reducing urine albumin excretion; returning patients to normoalbuminuria Not correlated with preventing ESRD Presented with statements re: recommendations for using ARBs in hypertensive diabetics; diabetes and hypertension being the two leading causes of ESRD, etc.

5 Cubicin Warning Letter Journal advertisement and website Broadens the indication treatment of all infections caused by Staph aureus PI states it is not indicated for pneumonia In Phase 3 studies of community-acquired pneumonia, death rate was higher

6 Xeloda Warning Letter Sales aid Promotion of unapproved uses Failed to convey specific indications Mechanism of action claims

7 Xeloda Warning Letter Mechanism of action claims Prominently featured bar graph depicting distribution of TP and listing of various tissues types Claim above graph Because TP activity is higher in most tumor tissue than in normal tissue, final conversion of drug to 5-FU occurs preferentially in the tumor Relationship of mechanism of action to efficacy and safety outcomes has not been demonstrated

8 Pravachol Warning Letter DTC ads and labeling pieces Healthcare professional directed labeling pieces Promotion of unapproved uses

9 Pravachol: Promotion of Unapproved Uses Not indicated to reduce risk of strokes in patients who do not have clinically evident CHD Claims WORRIED ABOUT HAVING A HEART ATTACK? WORRIED ABOUT HAVING A STROKE? PRAVACHOL IS THE ONLY CHOLESTEROL LOWERING DRUG PROVEN TO HELP PROTECT 1ST AND 2ND HEART ATTACKS AND STROKE

10

11 DDMAC Information Web addresses: www.fda.gov/cder/ddmac Warning and untitled letters : Posted on www.fda.gov/cder/warn Guidances: Posted on www.fda.gov/cder/guidance Phone numbers: (301) 827-2831 or (301) 827-2828

Download ppt "The Role of the FDA Thomas Abrams, R.Ph., M.B.A. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration October 26, 2004."

Similar presentations

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
@ PMCQ U October 19, 2004. Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.

@ PMCQ U October 19, Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.
PMAD 385: Critical Analysis of Pharmaceutical Marketing Historic Examples of Unsafe or Misleading Pharmaceutical Marketing Bruce Lambert, Ph.D. Pharmacy.

PMAD 385: Critical Analysis of Pharmaceutical Marketing Historic Examples of Unsafe or Misleading Pharmaceutical Marketing Bruce Lambert, Ph.D. Pharmacy.
FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,

FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,
National Institute for Health and Clinical Excellence.

National Institute for Health and Clinical Excellence.
The Role of Risk Information in Product Labeling Catherine Gray, PharmD Management Advisor Division of Drug Marketing, Advertising, and Communications.

The Role of Risk Information in Product Labeling Catherine Gray, PharmD Management Advisor Division of Drug Marketing, Advertising, and Communications.
RAC Study Group Chapter 16

RAC Study Group Chapter 16
Special Topics in IND Regulation

Special Topics in IND Regulation
© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any manner.

© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any manner.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.

Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
CHRONIC KIDNEY FAILURE

CHRONIC KIDNEY FAILURE
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.

Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
© 2009 Hogan & Hartson LLP. All rights reserved. Meredith Manning Partner May 20, 2009 FDA’s Internet Ad Warnings: Implications for Social Media National.

© 2009 Hogan & Hartson LLP. All rights reserved. Meredith Manning Partner May 20, 2009 FDA’s Internet Ad Warnings: Implications for Social Media National.
Division of Drug Marketing, Advertising, and Communications Enforcement Webinar Sangeeta Vaswani Chatterjee, Regulatory Counsel Team Leader Marissa Chaet.

Division of Drug Marketing, Advertising, and Communications Enforcement Webinar Sangeeta Vaswani Chatterjee, Regulatory Counsel Team Leader Marissa Chaet.
Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.

Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.
Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
Office of Prescription Drug Promotion Enforcement Webinar Robert Dean, Director, Division of Consumer Drug Promotion Andrew Haffer, Director, Division.

Office of Prescription Drug Promotion Enforcement Webinar Robert Dean, Director, Division of Consumer Drug Promotion Andrew Haffer, Director, Division.
The Value of Medication Therapy Management Services.

The Value of Medication Therapy Management Services.

Similar presentations

Ads by Google